IFN-associated depression can lead to deterioration in quality of life, and has become a major contribution to treatment withdrawal, non-compliance, dose reduction of IFN/RBV, and even attempted suicide [8]–[15]; all of which can result in treatment failure [16]–[18]. This evidence concerns the gene IFNA1 and depressive symptom measurement.